期刊文献+

湖北人群CYP2D6多态性的初步研究 被引量:4

Analysis of CYP2D6 gene polymorphism of Chinese population in Hubei
下载PDF
导出
摘要 目的初步研究湖北人群中CYP2D6基因的多态性,为后续的应用研究打下基础。方法采集137例志愿者静脉血,采用限制性片段长度多态性聚合酶链反应(PCR-RFLP)法分析CYP2D6*10基因多态性,测序法验证结果,哈迪-温伯格平衡定律检测基因型分布,卡方检验进行验证,并将结果和以往文献相比较。结果经测序验证,137例样本中,野生型(CC)为35例,出现频率为25.5%;杂合子(CT)为52例,出现频率为38.0%;突变型(TT)为50例,出现频率为36.5%,C等位基因的频率为44.5%,T等位基因的频率为55.5%,和以往研究结果相比,差异无统计学意义(P>0.05)。结论湖北人群中CYP2D6*10存在较高突变频率,在人群中开展基因分型对正确指导临床用药十分有必要。 Objective To preliminary study the distribution of CYP2 D6 polymorphism in Hubei population,with the intention of solid base for further applied research.Methods Venous blood was collected from137 volunteers,analysed CYP2 D6 * 10 Gene Polymorphism by using polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP)method.genotypes can be distinguished by agarose gel electrophoresis and gene sequencing.Hardy-Weinberg equilibrium law could be used to detect whether the genotype distribution was balanced,and chi-square test was used for verification,and the results were compared with the previous literature.Results Among the 137 samples,wild type(CC)was 35,the frequency was 25.5%.Heterozygote(CT)was 52,the frequency was 38.0%.And mutant(TT)was 50,the frequency was 36.5%.Also,C allele frequency was 44.5% while the T allele was 55.5%.There was no statistical difference compared with previous studies(P〉0.05).Conclusion Since there is a high mutation frequency of CYP2 D6*10 in Hubei population,it is very necessary to carry out genotyping to guide clinical medication correctly.
作者 曾嵘 毛晓兵 刘湘 黄婧 ZENG Rong;MAO Xiaobing;LIU Xiang;HUANG Jing(School of Laboratory Medicine,Hubei University of Chinese Medicine,Wuhan,Hubei 430065,Chin)
出处 《国际检验医学杂志》 CAS 2018年第13期1540-1542,1546,共4页 International Journal of Laboratory Medicine
基金 中国博士后科学基金面上项目(2014M552023) 湖北省自然科学基金面上项目(2014CFB220)
关键词 CYP2D6基因 多态性 限制性片段长度多态性聚合酶链反应 CYP2D6 gene polymorphism polymerase chain reaction restriction fragment length polymorphism
  • 相关文献

参考文献5

二级参考文献40

  • 1陈騉,王睿.药物代谢酶细胞色素P4502C9研究进展[J].中国临床药理学与治疗学,2004,9(6):601-606. 被引量:15
  • 2Bradford L D.CYP2D6 allele frequency in European Caucasians,Asians,Africans and their descendants[J].Pharmacogenomics,2002,3(2):229~243.
  • 3Zanger U M,Fischer J,Raimundo S,et al.Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6[J].Pharmacogenetics,2001,11(7):573~585.
  • 4Fukuda T,Nishida Y,Imaoka S,et al.The decreased in vivo clearance of CYP2D6 substrates by CYP2D6 * 10 might be caused not only by the low-expression but also by low affinity of CYP2D6[J].Arch Biochem Biophys,2000,380(2):303~308.
  • 5Yu A,Kneller B M,Rettie A E,et al.Expression,purification,biochemical characterization,and comparative function of human cytochrome P450 2D6.1,2D6.2,2D6.10 and 2D6.17 allelic isoformsIJ].J PharmacoL Exp Ther,2302,3(16(3):1291~1300.
  • 6Raimundo S,Fischer J,Eichelbaum M,et al.Elucidation of the genetic basis of the contain intermediate metabohzer' phonotype for drug oxidation by CYP2D6[J].Pharmacogenetics,2000,10(7):577~581.
  • 7LOvlie R,Daly A K,Matre G E,et al.Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype:a role for the CYP2D6 * 35 allele in ultrarapid metabolism?[J].Pharmacogenetics,2001,11 (1):45~55.
  • 8Zanger U M,Raimundo S,Eichelbaum M.Cytochrome P450 2D6:overview and update on pharmacology,genetics,biochemistry[J].Naunyn-Schmiedeberg's Arch Pharmacol,2004,369:23~37.
  • 9Kirchheiner J,Nickchen K,Bauer M,et al.Pharmacogenetics of antidepressants and antipsychotics:the contribution of allelic variations to the phenotype of drug response[J].Mol Psychiatry,2004,9 (5):442~473.
  • 10Chou W H,Yan F X,de Leon J,et al.Extension of a pilot study:impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness[J].J Clin Psychopharmacol,2000,20(2):246~251.

共引文献82

同被引文献27

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部